CAR-T cell therapy and infection: a review

References

• Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531–2544.
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45–56.
   PubMed Web of Science ®Google Scholar
• Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439–448.
   PubMed Web of Science ®Google Scholar
• U.S. National Institute of Health. Clinical trials registry [ Internet]. 2020. Available from: clinicaltrials.gov [Cited 2020 Jun 16]
   Google Scholar
• Vora SB, Waghmare A, Englund JA, et al. Infectious complications following CD19 chimeric antigen receptor T-cell therapy for children, adolescents and young adults. Open Forum Infect Dis [ Internet]. [cited 2020 Apr 24]; 7. Available from: https://academic.oup.com/ofid/article/doi/10.1093/ofid/ofaa121/5818307
   PubMed Web of Science ®Google Scholar
• Hill JA, Li D, Hay KA, et al. Infectious complications of CD19-targeted chimeric antigen receptor–modified T-cell immunotherapy. Blood. 2018;131:121–130.
   PubMed Web of Science ®Google Scholar
• Park JH, Romero FA, Taur Y, et al. Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with chimeric antigen receptor T cells. Clinl Infect Dis. 2018;67:533–540.
   PubMed Web of Science ®Google Scholar
• Teh BW, Harrison SJ, Worth LJ, et al. Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy. Br J Haematol. 2015;171:100–108.
   PubMed Web of Science ®Google Scholar
• Teh BW, Teng JC, Urbancic K, et al. Invasive fungal infections in patients with multiple myeloma: a multi-center study in the era of novel myeloma therapies. Haematologica. 2015;100:e28–e31.
   PubMed Web of Science ®Google Scholar
• Cheson BD. Infectious and immunosuppressive complications of purine analog therapy. JCO. 1995;13:2431–2448.
   PubMed Web of Science ®Google Scholar
• O’Brien SM, Kantarjian HM, Cortes J, et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. JCO. 2001;19:1414–1420.
   PubMed Web of Science ®Google Scholar
• Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016;127:3321–3330.
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119:2709–2720.
   PubMed Web of Science ®Google Scholar
• Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507–1517.
   PubMed Web of Science ®Google Scholar
• Ali S, Kjeken R, Niederlaender C, et al. The European Medicines Agency review of Kymriah (Tisagenlecleucel) for the treatment of acute lymphoblastic leukemia and diffuse large B‐cell lymphoma. Oncologist [ Internet]. 2020 [cited 2020 Mar 30];25. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1634/theoncologist.2019-0233
   Web of Science ®Google Scholar
• Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188–195.
   PubMed Web of Science ®Google Scholar
• Fried S, Avigdor A, Bielorai B, et al. Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transplant. 2019;54:1643–1650.
   PubMed Web of Science ®Google Scholar
• Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol. 2019;20:31–42.
   PubMed Web of Science ®Google Scholar
• Cordeiro A, Bezerra ED, Hirayama AV, et al. Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells. Biol Blood Marrow Transplant. 2020;26:26–33.
   PubMed Web of Science ®Google Scholar
• Luo H, Wang N, Huang L, et al. Inflammatory signatures for quick diagnosis of life-threatening infection during the CAR T-cell therapy. J Immunother Cancer [ Internet]. 2019 [cited 2020 Mar 30];7. Available from: http://jitc.bmj.com/lookup/doi/10.1186/s40425-019-0767-x
   Web of Science ®Google Scholar
• Wudhikarn K, Palomba ML, Pennisi M, et al. Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma. Blood Cancer J [ Internet]. 2020 [cited 2020 Aug 10];10. Available from: http://www.nature.com/articles/s41408-020-00346-7
   PubMed Web of Science ®Google Scholar
• Li C, Zhang Y, Zhang C, et al. Comparison of CAR-T19 and autologous stem cell transplantation for refractory/relapsed non-Hodgkin’s lymphoma. JCI Insight [ Internet]. 2019 [cited 2020 Mar 30];4. Available from: https://insight.jci.org/articles/view/130195
   Web of Science ®Google Scholar
• Young J-AH, Logan BR, Wu J, et al. Infections after transplantation of bone marrow or peripheral blood stem cells from unrelated donors. Biol Blood Marrow Transplant. 2016;22:359–370.
   PubMed Web of Science ®Google Scholar
• Hay KA, Hanafi L-A, Li D, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood. 2017;130:2295–2306.
   PubMed Web of Science ®Google Scholar
• Budde LE, Zaia JA. CD19 CAR-T therapy and sepsis: dancing with the devil. Blood. 2018;131:7–8.
   PubMed Web of Science ®Google Scholar
• Torres HA, McDonald GB. How I treat hepatitis C virus infection in patients with hematologic malignancies. Blood. 2016;128:1449–1457.
   PubMedGoogle Scholar
• Mayer KH, Torres HA, Mulanovich V. Management of HIV infection in patients with cancer receiving chemotherapy. Clin Infect Dis. 2014;59:106–114.
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu Y, Tan X, et al. Safety and efficacy of chimeric antigen receptor (CAR)-T-cell therapy in persons with advanced B-cell cancers and hepatitis B virus-infection. Leukemia [Internet]. 2020 [cited 2020 Aug 17]; 34:2704–2707. Available from: http://www.nature.com/articles/s41375-020-0936-4
   Web of Science ®Google Scholar
• Lai P, Chen X, Qin L, et al. The efficacy and safety of CAR-T cell therapy in patients with refractory ALL and concomitant HBV infection. Leukemia. 2020;34:2790–2793.
   PubMed Web of Science ®Google Scholar
• Strati P, Nastoupil LJ, Fayad LE, et al. Safety of CAR T-cell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection. Blood. 2019;133:2800–2802.
   PubMed Web of Science ®Google Scholar
• Wei J, Zhu X, Mao X, et al. Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma. J Immunother Cancer [ Internet]. 2019 [cited 2020 Aug 14];7. Available from: http://jitc.bmj.com/lookup/doi/10.1186/s40425-019-0790-y
   Web of Science ®Google Scholar
• Abramson JS, Irwin KE, Frigault MJ, et al. Successful anti‐CD19 CAR T‐cell therapy in HIV‐infected patients with refractory high‐grade B‐cell lymphoma. Cancer. 2019;125:3692–3698.
   PubMed Web of Science ®Google Scholar
• Ariza-Heredia EJ, Granwehr BP, Viola GM, et al. False-positive HIV nucleic acid amplification testing during CAR T-cell therapy. Diagn Microbiol Infect Dis. 2017;88:305–307.
   PubMed Web of Science ®Google Scholar
• Sdrimas K, Diaz-Paez M, Camargo JF, et al. Progressive multifocal leukoencephalopathy after CAR T therapy. Int J Hematol [Internet]. 2020 [cited 2020 Apr 3]; 112:118–121.
   PubMed Web of Science ®Google Scholar
• Novartis Pharmaceuticals Corporation. KYMRIAH (tisagenlecleucel) prescribing information. New Jersey: Novartis; 2018.
   Google Scholar
• Kite Pharma Inc. YESCARTA (axicabtagene ciloleucel) prescribing information. Santa Monica (CA): Kite Pharma Inc; 2018.
   Google Scholar
• Taplitz RA, Kennedy EB, Bow EJ, et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. J Clin Oncol. 2018;36:3043–3054.
   PubMed Web of Science ®Google Scholar
• Haidar G, Dorritie K, Farah R, et al. Invasive mold infections after chimeric antigen receptor–modified T-cell therapy: a case series, review of the literature, and implications for prophylaxis. Clinl Infect Dis [ Internet]. 2019 [cited 2020 Mar 30]; Available from: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciz1127/5637933
   Web of Science ®Google Scholar
• Hill JA, Seo S. How we prevent infections in patients receiving CD19-targeted chimeric antigen receptor T-cells for B-cell malignancies. Blood [ Internet]. [cited 2020 Aug 14];136:925–935. Available from: https://ashpublications.org/blood/article/doi/10.1182/blood.2019004000/461120/How-we-prevent-infections-in-patients-receiving
   Web of Science ®Google Scholar
• Lindsay J, Teh BW, Micklethwaite K, et al. Azole antifungals and new targeted therapies for hematological malignancy. Curr Opin Infect Dis. 2019;32:538–545.
   PubMed Web of Science ®Google Scholar
• Mahmoudjafari Z, Hawks KG, Hsieh AA, et al. American society for blood and marrow transplantation pharmacy special interest group survey on chimeric antigen receptor T cell therapy administrative, logistic, and toxicity management practices in the United States. Biol Blood Marrow Transplant. 2019;25:26–33.
   PubMed Web of Science ®Google Scholar
• Hill JA, Giralt S, Torgerson TR, et al. CAR-T – and a side order of IgG, to go? – immunoglobulin replacement in patients receiving CAR-T cell therapy. Blood Rev. 2019;38:100596.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMA). KYMRIAH: EPAR - Product Information. 2018.[ Internet]. [Cited 2020 Jun 11]  Available from: https://www.ema.europa.eu/en/documents/product-information/kymriah-epar-product-information_en.pdf
   Google Scholar
• Santomasso BD, Park JH, Salloum D, et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov. 2018;8:958–971.
   PubMed Web of Science ®Google Scholar
• Sachdeva M, Duchateau P, Depil S, et al. Granulocyte–macrophage colony-stimulating factor inactivation in CAR T-cells prevents monocyte-dependent release of key cytokine release syndrome mediators. J Biol Chem. 2019;294:5430–5437.
   PubMed Web of Science ®Google Scholar
• Galli E, Allain V, Di Blasi R, et al. G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory/relapsed B-cell lymphoma. Bone Marrow Transplant. 2020;55:2347–2349.
   PubMed Web of Science ®Google Scholar
• Bhoj VG, Arhontoulis D, Wertheim G, et al. Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy. Blood. 2016;128:360–370.
   PubMed Web of Science ®Google Scholar
• Hill JA, Krantz EM, Hay KA, et al. Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy. Blood Adv. 2019;3:3590–3601.
   PubMed Web of Science ®Google Scholar
• Kansagra AJ, Frey NV, Bar M, et al. Clinical utilization of Chimeric antigen receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). Bone Marrow Transplant. 2019;54:1868–1880.
   PubMed Web of Science ®Google Scholar
• Jain T, Bar M, Kansagra AJ, et al. Use of Chimeric antigen receptor T cell therapy in clinical practice for relapsed/refractory aggressive B cell non-Hodgkin lymphoma: an expert panel opinion from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2019;25:2305–2321.
   PubMed Web of Science ®Google Scholar
• Yakoub-Agha I, Chabannon C, Bader P, et al. Management of adults and children undergoing CAR t-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica [ Internet]. 2019 [cited 2020 Apr 3]. Available from: http://www.haematologica.org/content/early/2019/11/18/haematol.2019.229781
   Web of Science ®Google Scholar